HC Wainwright Comments on Xeris Biopharma Q2 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Stock analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for Xeris Biopharma in a note issued to investors on Monday, March 2nd. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of $0.01 per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Xeris Biopharma’s Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $0.06 EPS, FY2027 earnings at $0.17 EPS, FY2028 earnings at $0.36 EPS, FY2029 earnings at $0.66 EPS and FY2030 earnings at $0.91 EPS.

XERS has been the subject of several other reports. Oppenheimer restated an “outperform” rating and set a $18.00 price objective on shares of Xeris Biopharma in a research report on Friday, November 7th. Piper Sandler lifted their price target on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Barclays initiated coverage on shares of Xeris Biopharma in a report on Monday, December 8th. They issued an “overweight” rating and a $9.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, January 21st. Finally, Wall Street Zen cut shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Xeris Biopharma has an average rating of “Moderate Buy” and an average price target of $10.08.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock opened at $6.04 on Wednesday. The company has a current ratio of 2.19, a quick ratio of 1.35 and a debt-to-equity ratio of 16.10. The company has a market cap of $1.04 billion, a PE ratio of -603.40 and a beta of 0.61. The company has a 50 day moving average of $7.13 and a 200-day moving average of $7.60. Xeris Biopharma has a 1-year low of $3.81 and a 1-year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. The firm had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million.

Institutional Trading of Xeris Biopharma

Several institutional investors have recently modified their holdings of the business. Kestra Advisory Services LLC bought a new position in Xeris Biopharma during the 4th quarter worth $25,000. AlphaQuest LLC bought a new position in shares of Xeris Biopharma during the third quarter worth about $35,000. Caitong International Asset Management Co. Ltd raised its position in shares of Xeris Biopharma by 9,276.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after acquiring an additional 7,421 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Xeris Biopharma by 179.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after acquiring an additional 5,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after acquiring an additional 1,820 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

Insider Buying and Selling

In other Xeris Biopharma news, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $7.43, for a total transaction of $123,835.81. Following the sale, the insider directly owned 1,308,103 shares of the company’s stock, valued at $9,719,205.29. The trade was a 1.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $7.09, for a total transaction of $106,350.00. Following the completion of the transaction, the director owned 142,500 shares of the company’s stock, valued at approximately $1,010,325. This trade represents a 9.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 240,308 shares of company stock valued at $1,732,453 over the last three months. Insiders own 6.47% of the company’s stock.

Xeris Biopharma News Summary

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating with a $10 price target and published multi‑year EPS upside through 2030, signalling continued analyst conviction in the company’s pipeline and revenue trajectory. HC Wainwright coverage / MarketBeat
• Positive Sentiment: A bullish third‑party piece argues Xeris is undervalued given its drug portfolio, which can attract value/growth investors and support longer‑term demand for the stock. Seeking Alpha: Undervalued thesis
• Positive Sentiment: Aggregate analyst coverage is summarized as a “Moderate Buy,” which helps underpin investor sentiment versus outright bearish coverage. Consensus rating / American Banking News
• Neutral Sentiment: HC Wainwright published specific near‑term estimates (Q1‑2026 EPS est. of ($0.03); FY2026 est. $0.06) that give a roadmap for upcoming results but include mixed signals as Xeris transitions toward expected profitability. HC Wainwright estimates / MarketBeat
• Neutral Sentiment: Consensus full‑year EPS remains negative (around ‑$0.41), so near‑term profitability risk persists until revenue and margin trends consistently improve. Consensus estimates / MarketBeat
• Negative Sentiment: Insider Beth Hecht sold 16,667 shares at an average $6.25 on Mar 2 (Form 4 filed), which some investors view as a negative signal about insider conviction or a source of incremental supply. Insider sale alert / InsiderTrades
• Negative Sentiment: HC Wainwright trimmed several mid/long‑range EPS forecasts (FY2026‑FY2029 revisions downward), reducing some near‑term upside and tempering expectations until revenue growth reaccelerates. Forecast revisions / MarketBeat

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.